Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.
Chimeric antigen receptor (CAR)-T cell therapy is generating excitement across blood cancers, and may eventually be an appealing option for patients with mantle cell lymphoma (MCL), said Andre Goy, M.D., M.S., chief, Division of Lymphoma, chairman and director of the John Theurer Cancer Center.
The ongoing ZUMA-2 trial is exploring the possibility of CAR-T cell therapy in patients with relapsed or refractory MCL. While official results are not out yet, Goy mentioned that the researchers are seeing a high response rate and promising results in this patient population.
Goy said that CAR-T cell therapy is particularly appealing in patients with MCL who eventually develop a resistance to chemotherapy. CAR-T cells can offer a new line of therapy in a setting that traditionally had very few options.
